Targeting angiogenesis in pancreatic cancer

The Lancet

Volumn 371, Issue 9630, 2008, Pages 2062-2064

  Philip, Philip A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BINDING PROTEIN; GEMCITABINE; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADD ON THERAPY; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; KIDNEY CANCER; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 45449087897     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60770-9     Document Type: Note

References (16)

1. Kleeff J., Beckhove P., Esposito I., et al. Pancreatic cancer microenvironment. Int J Cancer 121 (2007) 699-705
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
3. Sandler A., Gray R., Perry P., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
4. Kindler H., Niedzwiecki D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25 suppl (2007) 4508 (abstr).
5. Kindler H., Friberg G., Singh D., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
6. Duffy J., Eibl G., Reber H., and Hines O. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2 (2003) 12
7. Cabebe E., and Fisher G. Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Expert Opin Investig Drugs 16 (2007) 467-476
8. Buchler P., Reber H., Buchler M., Friess H., and Hines O. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236 (2002) 738-749
9. Escudier B., Eisen T., Stadler W., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
10. Spano J.-P., Chodkiewicz C., Maurel J., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 10.1016/S0140-6736(08)60661-3 published online May 30
11. Song S., Ewald J., Stallcup W., Werb Z., and Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7 (2005) 870-879
12. Pfizer. Randomized study of gemcitabine plus AG-013736 versus gemcitabine for advanced pancreatic cancer. April, 2008. http://clinicaltrials.gov/ct2/show/NCT00471146?term=axitinib&rank=7 (accessed May 23, 2008).
13. Abdollahi A., Schwager C., Kleeff J., et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 104 (2007) 12890-12895
14. Friess H., Langrehr J., Oettle H., et al. A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6 (2006) 285
15. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2 (2003) 8
16. Sanofi-Aventis. Aflibercept compared to placebo in terms of efficacy in patients treated with gemcitabine for metastatic pancreatic cancer (April, 2008). http://clinicaltrials.gov/ct2/show/NCT00574275?term=aflibercept&rank =3 (accessed May 23, 2008).